Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3+ resident memory CD8+ T cells and multiple chemokine pathways.

In Dermatology
by ClinOwl April 23, 2021

The use of immune checkpoint inhibitors (ICI), such as anti-programmed cell death-1 (PD-1) antibodies, has profoundly changed melanoma prognosis. However, only 35% to 45% of patients experience durable responses, highlighting […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3+ resident memory CD8+ T cells and multiple chemokine pathways.